85 results about "CD14" patented technology

The invention belongs to the technical field of tumor micro-immune environments, and particularly relates to a kit for detecting a tumor micro-environment, a detection method and application, the kit comprises rare metal element labeled monoclonal antibodies, the rare metal element labeled monoclonal antibodies comprise 115In-CD20, 139La-Histone H3, 142Nd-CD56, 144Nd-CD14, 146Nd-Vimentin, 148Nd-Pan-CK, 151Eu-CD31, 156Gd-CD4, 158Gd-E-Cadrin, 159Tb-CD68, 162Dy-CD8a, 166Er-CD45, 167Er-CD15, 170Er-CD3, 171Yb-CD11c and 209Bi-alpha-SMA, and the rare metal element labeled monoclonal antibodies comprise The invention can be used for simultaneously detecting and researching the quantity, positioning and spatial topological relation of each cell component in a tumor microenvironment, and provides a multi-immunofluorescence detection kit and method for ubiquitous epithelial differentiation-derived tumors based on an imaging mass spectrum flow technique. A plurality of biomarkers can be analyzed at the same time by using multiple immunohistochemical staining and rare earth metal tag signal detection technologies, so that the aim of performing high-dimensional analysis on a tumor microenvironment is fulfilled according to cell composition, functional state and cell-cell space interaction relationship.

The invention discloses a kit and method for detecting leukemia and lymphoma based on full-spectrum flow cytometry, the kit comprises 25 antibodies, the antibodies are specifically bound with fluorescein respectively, and leukemia and lymphoma are detected through full-spectrum flow cytometry; the 25 kinds of antibodies comprise HLA-DR (human leukocyte antigen-DR), CD38, CD7, CD34, Lambda, CD19, CD64, CD14, CD5, CD123, CD16, CD20, Kappa, CD117, CD13, CD45, CD11b, CD2, CD10, CD8, CD15, CD4, CD3, CD56 and CD33. The kit comprehensively covers development stages of various lines of bone marrow cells, and common abnormal expressions of various leukemia, myelodysplastic syndromes and lymphoma, and can preliminarily screen various leukemia and lymphoma.

The invention discloses a reagent for rapidly distinguishing bacterial and virus infection and application, belongs to the field of molecular biology, relates to medical and biotechnology, and aims to solve the problem that a traditional method cannot clearly distinguish bacterial infection from virus infection. The reagent comprises five antibodies marked with different fluorescence. The five antibodies are all mouse anti-human or rabbit anti-human antibodies, and targets corresponding to the five antibodies are respectively CD45, CD14, CD64, CD169 and HLA-DR (human leukocyte antigen-DR). The tail end of the antibody is connected with different fluorescein through chemical reaction; fluorescence labeling is performed on neutrophils, mononuclear cells and lymphocytes in peripheral blood through an antibody combination of CD molecules, and corresponding infection indexes are calculated through a flow cytometry method, so that the infection type (bacterial / virus infection) of a patient is quickly distinguished and judged.

The invention discloses application of hesperidin in preparation of a medicine for preventing and / or treating porcine contagious pleuropneumonia, and belongs to the field of biological medicine. The concentration of the hesperidin is 6.25-25 [mu] g / mL, and cell experiments prove that the hesperidin can inhibit cell inflammatory response and reduce expression of inflammatory factors, and can effectively relieve the actinobacillus pleuropneumoniae induced endovascular dermatitis injury by inhibiting activation of CD14 / TLR4-NF [kappa] B P65. Animal experiments prove that the hesperidin can relieve pathological changes and injuries of various tissues and organs after actinobacillus pleuropneumoniae infection, improve weight loss caused by actinobacillus pleuropneumoniae infection, relieve inflammatory response and metabolic dysfunction caused by actinobacillus pleuropneumoniae, and improve the body weight loss caused by actinobacillus pleuropneumoniae. The composition plays a role in protecting organisms infected by actinobacillus pleuropneumoniae. The invention provides a new scientific basis for controlling porcine contagious pleuropneumonia by using natural medicines.

The invention discloses a bifunctional T cell adapter targeting CD14 and CD3 and an application of the bifunctional T cell adapter. Specifically, the invention provides a CD14 and CD3 targeting bifunctional T cell adapter, the CD14 and CD3 targeting bifunctional T cell adapter comprises a skeleton containing an IgG antibody constant region, the skeleton comprises two heavy chains and a light chain, one heavy chain comprises heavy chain constant regions CH1, CH2 and CH3, the other heavy chain comprises CH2 and CH3, the light chain comprises CL, the CD14 and CD3 targeting bifunctional T cell adapter is a heterotrimer, and the CD14 and CD3 targeting bifunctional T cell adapter is a heterotrimer. Specifically, the first subunit comprises a light chain variable region of an anti-CD14 antibody and a light chain in the skeleton, the second subunit comprises a heavy chain variable region of the anti-CD14 antibody and a heavy chain in the skeleton, and the third subunit comprises a heavy chain variable region of an anti-CD3 antibody and a light chain variable region. The bifunctional T cell adapter disclosed by the invention has an excellent tumor killing effect.

The invention discloses an antibody composition for detecting mother cell plasma cell-like dendritic cells. The antibody composition comprises a first group of antibodies, a second group of antibodies, a third group of antibodies and a fourth group of antibodies, the first group of antibodies comprises a CD36 antibody, a CD4 antibody, a CD14 antibody, a CD56 antibody, a CD5 antibody, a CD3 antibody, a CD8 antibody, a CD2 antibody, a CD7 antibody and a CD45 antibody; the second group of antibodies comprises an HLA-DR (Human Leukocyte Antigen-DR) antibody, a CD33 antibody, a CD34 antibody, a CD56 antibody, a CD117 antibody, a CD123 antibody, a CD19 antibody, a CD38 antibody and a CD45 antibody; the third group of antibodies comprises a CD303 antibody, a CD304 antibody, a CD41 antibody, a CD56 antibody, a CD13 antibody, a CD85j antibody, a CD64 antibody, a CD15 antibody and a CD45 antibody; and the fourth group of antibodies comprises TdT, MPO, CD56, cCD3, CD10, cCD22 and CD45 antibodies. The antibody composition can be used for accurately detecting tumor abnormal BPDCN cells.

To provide methods for preparing novel immunoregulatory macrophage cells which are useful in the treatment of different immunological and non-immunological diseases and conditions; resulting macrophage cells; and pharmaceutical compositions comprising macrophage cells.SOLUTION: A method for preparing an immunoregulatory macrophage cell is provided, the method comprising: (a) isolating CD14 positive monocytes from a blood sample of a subject; (b) culturing the monocytes in a gas-permeable bag in a culture medium containing (i) M-CSF and / or GM-CSF, and (ii) a CD16 ligand; (c) contacting the cells with IFN-γ; and (d) obtaining the immunoregulatory macrophage cell from the culture medium.SELECTED DRAWING: Figure 10

Provided are: an adeno-associated virus (AAV) vector, the AAV vector comprising a cytokine gene, and the cytokine being selected from any one or two or more of the following: IL3, GM-CSF, IL6, APRIL, and BAFF; an AAV vector combination comprising any two or three or more of said AAV vectors; and a method for constructing an acute myeloid leukemia xenograft non-human animal and a method for constructing a multiple myeloma xenograft non-human animal. In addition, further provided is another adeno-associated virus (AAV) vector, the AAV vector comprising a cytokine gene, and the cytokine being selected from any one or two or more of the following: IL2, IL3, IL6, IL15, THPO, SCF, and GM-CSF; further provided is an AAV vector combination comprising any two or three or more of said AAV vectors; and further provided is the use of the AAV vector and AAV vector combination in the construction of a humanized immune system non-human animal, as well as a method for constructing a humanized immune system non-human animal and a method for promoting the differentiation of human hematopoietic stem cells into CD14+ monocytes and CD66b+ granulocytes.

Provided herein are engineered or modified cell lines in which the expression of at least one of ADM2, AURKA, BCL2, CCND1, CHD1, CREB3L3, RIGI / DDX58, ECSIT, EHHADH, ERBB2, FAS, FBXW7, FGFR3, FOXL2, GATA1, HDAC5, HOXA5, HSP90B1, IL6, ITGA2B, KAT5, LAS1L, LIF, NFKB1, NFKB2, NFKB1A, NFE2L2, NGEF, NME1, NR3C1, POLN, PPAR-A, PTEN, RELB, RPA1, RXRA, SMAD4, SS18, TCF7, TGM2, THEM6, TNFAIP3, TP63, TRPC1, DBH, ITGAM, HHEX, TXNIP, ASNS, PLEKH02, CDKN1A, C5orf64, COL20A1, GJB3, ISYNA1, PARD6G-AS1, ACTA1, ACTC1, ADCY10, ADCY4, ADORA2A, ALKBH5, ATP1A4, ATP1B2, ATP2B2, BAIAP3, BAZ1B, BTK, CBL, CCNA1, CD14, CLTC, COPS3, CRHR2, CXADR, DAPK1, DCTN5, DYNLRB1, EME2, EXOC3L1, EYA3, EYA4, FANCA, FEN1, GAK, GCGR, GHSR, GSK3B, H2BC5, H4C7, H4C8, HAP1, HCAR1, INO80, KCNB1, LAT2, LIN7C, MAP1B, MBD4, MYH11, MYH15, MYH3, MYH7B, NAPA, NKD2, NLRP5, NPM2, NR4A3, NFRKB, PAXIP1, PIAS1, PIAS4, POLE, POLE3, POLD1, POLH, PPP4R2, PTGER3, RAB25, RAB40C, RAB44, RAD9A, REV1, RIF1, RNF111, RNF168, RNF4, RPA4, RTEL1, SCRIB, SNRNP70, SPHK1, STX3, SYT1, SYT2, SYT5, SYTL1, SYNJ2, TERF2, TNFSF10, TNPO2, TOP3A, TRIM25, TRIM72, TXLNA, UBA7, UNC5A, VAV3, VPS18, WASL, XRN2, and YY1 is altered as compared to a control cell line. Also provided are methods of producing recombinant AAV particles in said engineered or modified cell lines.

The invention relates to the technical field of biological medicine, in particular to application of S100A9 protein to preparation of a product for predicting the recurrence risk of AML. The product is used for detecting a marker CD15, a marker CD33, a marker CD14, a marker CD15, a marker CD33, a marker CD64, a marker CD5, a marker CD14, a marker CD10, a marker CD19, a marker CD33, a marker CD34, a marker CD64, a marker CD117, a marker CD13 or a marker CD45. Therefore, the accuracy of predicting the AML recurrence risk is improved.

This invention discloses a bifunctional T-cell connector targeting CD14 and CD3 and its application. Specifically, this invention provides a bifunctional T-cell connector targeting CD14 and CD3, comprising a backbone containing a constant region of an IgG antibody. The backbone includes two heavy chains and one light chain, wherein one heavy chain includes a heavy chain constant region CH1, CH2, and CH3, and the other heavy chain includes CH2 and CH3. The light chain includes CL. The bifunctional T-cell connector targeting CD14 and CD3 is a heterotrimer, specifically: a first subunit includes a variable region of the light chain of an anti-CD14 antibody and the light chain in the backbone; a second subunit includes a variable region of the heavy chain of an anti-CD14 antibody and one heavy chain in the backbone; and a third subunit includes a variable region of the heavy chain of an anti-CD3 antibody and a variable region of the light chain. The bifunctional T-cell connector of this invention exhibits excellent tumor-killing effects.

The invention discloses a method for detecting aortic dissection through peripheral blood BRD4 based on flow cytometry and application. The invention belongs to the technical field of biology, and particularly relates to a method for detecting aortic dissection through peripheral blood BRD4 based on flow cytometry and application. The method for detecting the content or expression level of the bromodomain-containing protein 4 in the sample to be detected comprises the following steps: 1) treating the sample to be detected to obtain mononuclear cells; the method comprises the following steps of (1) determining a mononuclear cell, (2) determining a fluorescein coupling antibody composition of a detection index according to a flow cytometry color matching scheme, (3) uniformly mixing the mononuclear cell in the step (1) and the fluorescein coupling antibody in the step (2), incubating in a dark place and dyeing, (4) loading and testing a sample by a spectrum flow cytometry, and (5) analyzing a data result, and the detection indexes in the step (2) are CD45, CD11B, CD66B, CD14, CC16 and BRD4.

The invention discloses a method for co-immunoculture of patient-derived tumor cell antigen peptide loaded by PBMC (peripheral blood mononuclear cells) and autologous DC (dendritic cells) and application of the method. The method comprises the following steps: extracting tumor-associated antigen peptide from a patient-derived tumor organ (PDO), and performing IFN-gamma pretreatment and freeze-thaw cycle purification; separating CD14 < + > mononuclear cells from the PBMC, inducing mature DCs (Dendritic Cells) by adopting a two-stage culture method, and loading antigens; and co-culturing the PBMC and the antigen-loaded DC, and detecting IFN-gamma expression after culturing for 48 hours. According to the method, the sensitivity and consistency of immunoreaction are remarkably improved, the experimental period is shortened, and the method is suitable for individualized drug screening and tumor immunity research.

The invention belongs to the technical field of biology, and particularly relates to application of CD14 gene / protein as a target spot to screening of drugs for preventing or treating African swine fever virus infection, the inventor uses host protein CD14 as a research object to explore the influence of the host protein CD14 on ASFV infected host cells, and research results show that the CD14 protein can promote adsorption, internalization and replication of ASFV, and the CD14 gene / protein can be used for preparing drugs for preventing or treating ASFV infection. The siRNA, the antibody and the recombinant protein of the CD14 can inhibit ASFV infected cells, and vaccines or drugs for preventing or treating African swine fever virus infection can be screened or anti-African swine fever CD14 knockout pigs can be screened by taking the CD14 gene / protein as a target spot. The invention enriches the cognition of the host protein for regulating and controlling ASFV infection, provides theoretical support for the research and development of safe and effective ASF vaccines, and has important significance for the clinical treatment and prevention and control of African swine fever.

The application of the biomarker combination in the preparation of a drug for fulminant myocarditis belongs to the field of drugs. The application is characterized in that the biomarker combination comprises Siglec-5; the biomarker combination is further selected from the group consisting of sST2, PAI-1, Siglec-5, CD163, CD40, P-Cadherin, CD14, CTLA4. The application finds that the expression of the biomarker in the plasma of a patient with fulminant myocarditis is increased, and confirms the role of the biomarker as a drug target in relieving and / or improving fulminant myocarditis. The level of the biomarker can be controlled by a drug, the diagnosis and subsequent treatment of the disease can be more intensified, and the biomarker has great application value in clinical practice.

The present disclosure provides a composition for treating or preventing fibrosis and / or inflammation in an organ or tissue in a subject. The present disclosure specifically provides a composition for treating or preventing fibrosis and / or inflammation in an organ or tissue in a subject, the composition containing macrophages derived from monocytes stimulated with IL-34. The composition can be produced by a method comprising: a step for preparing a sample comprising CD14-positive cells; an optional step for isolating the CD14-positive cells from the sample if required; and a step for bringing the sample or the isolated CD14-positive cells into contact with IL-34.

The invention provides an antibody composition for detecting immature mononuclear cells and application thereof, the antibody composition for detecting the immature mononuclear cells comprises a first group of antibodies and a second group of antibodies, the first group of antibodies comprises a CD15 antibody, a CD117 antibody, a CD34 antibody, a CD33 antibody, a CD14 antibody, an HLA-DR antibody, a CD13 antibody, a CD38 antibody, a CD64 antibody, a CD19 antibody, a CD56 antibody, a CD7 antibody and a CD45 antibody; and the second group of antibodies comprise an HLA-DR antibody, a CD64 antibody, a CD33 antibody, a CD14 antibody, a CD65 antibody and a CD45 antibody. According to the present invention, the flow cytometry is adopted to detect, and the antibody composition of the first group of antibodies and the second group of antibodies is provided, such that the detection sensitivity and the specificity are improved.

The invention discloses a method for identifying chronic granulocyte immune typing by using a flow cytometer. The method comprises the following steps: incubating and purifying a to-be-detected sample and a fluorescein-labeled antibody composition; the method comprises the following steps: carrying out flow cytometry detection on resuspended cells: firstly, circling a liquid flow stable interval by utilizing Time / CD45, FSC INT / PEAK and FSC INT / SSC INT scatter diagrams, and removing sticky bodies and cell debris; all leukocyte groups are circled through combination of CD45 and SSC, and mononuclear cells are circled in all leukocyte gates through CD45 / SSC gate setting; excluding CD 19 + B lymphocytes; cD7 + T and NK cells are excluded; cD2 + T and NK cells are eliminated; immature and mature granulocytes of CD 16 and CD24 < + > are excluded through CD 16 / CD24 gate setting; the method comprises the following steps of: screening CD14-CD16, removing basophilic granulocytes of CD14-CD16-and residual NK (Natural Killer) cells, dividing a cross gate to determine the proportion of CD 14 + CD16-cMo cells, CD 14 + CD16 + iMo cells and CD 16 + CD 14 ncMo cells, and determining the proportion of the CD14 + CD16-cMo cells, the CD14 + CD16 + iMo cells and the CD16 + CD14 ncMo cells; cD34 / SSC gate setting is carried out, and CD34 + original cells are circled to calculate the proportion.

The application relates to the technical field of medical detection, in particular to a kit, a method and a system for predicting bacterial infection. The application provides a kit for predicting bacterial infection, which comprises an antibody combination for specifically recognizing CD64, CD14 and CD14, and the antibodies are respectively labeled with mutually distinguishable fluorescent dyes. Meanwhile, the application provides a method for predicting bacterial infection, which comprises obtaining the counts of neutrophils, lymphocytes and monocytes in a to-be-detected sample, and the fluorescent intensities of CD64 and CD14 on the cell subgroups, and calculating four characteristic parameters IDXNLR, IDXLMR, IDXCD64 and IDXCD14; and then inputting the parameters into a pre-trained infection diagnosis model to output a risk score for judging the infection state (especially bacterial infection). The model significantly improves the accuracy and specificity of distinguishing bacterial infection from non-bacterial infection (such as viral infection or healthy state) by comprehensively integrating immune parameters in multiple dimensions.

The present disclosure relates to methods of manufacturing Chimeric Antigen Receptor (CAR) T cells. Notably, the manufacturing method omits the CD14+ / CD25+ depletion step. Additionally, by starting with CD62L enrichment of naïve and memory T cells, the resulting CAT T cells show reduced release of proinflammatory cytokines. Furthermore, the transduced cells show improved quiescence after removal of the transactivation agent.

Provided are neutrophils and monocytes having unique combinations of cell surface markers capable of enhancing TRAMlo neutrophil or monocyte subsets, or capable of reprogramming neutrophils and monocytes into TRAM deficient neutrophils and monocytes, including methods of isolating the neutrophils and monocytes for use in treating chronic inflammatory diseases. The enhanced or reprogramed neutrophils may express surface markers comprising CD177lo and at least one of Dectin2 (Clec4n)lo, EHD1lo, CD84hi, Ly6E / Ly6Ahi, CD200Rhi, CD24hi, CD49Dlo, or a combination thereof, and the enhanced or reprogrammed monocytes may express surface markers comprising CD14+, CD16+, and at least one of CD24hi, CD200Rhi, or CD84hi.

The invention belongs to the technical field of medicines, discloses application of a compound aureomycin A for preventing and treating leukemia by inducing differentiation of leukemia HL-60, and particularly discloses application of the compound aureomycin A shown in a formula (I) in inducing expression of mature macrophage markers CD11b, CD14 and CSF1R of leukemia HL-60 cells to induce cell differentiation for preventing and treating leukemia. Pharmacological experiments prove that the aureomycin A can be used for remarkably inducing the expression of CD11b, CD14 and CSF1R in leukemia HL-60 cells. Experimental results show that the aureomycin A has the effect of inducing leukemia cell differentiation to prevent and treat leukemia.

Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.

The invention discloses an analysis method for detecting the H3K27me3 level of each immune cell population in human whole blood by using flow cytometry, which comprises the following steps of: by a pretreatment mode of splitting red blood cells in a human whole blood sample by using a one-step method and fixing white blood cells, dyeing the split and fixed white blood cells by using fluorescently labeled antibodies (BV785-CD3, BV650-CD19, BV605-CD14, AF488-HLA-DR, AF647-H3K27 and Pacilic Blue-H3); and carrying out gate analysis on the sample after antibody staining by using a flow cytometer, and calculating the H3K27me3 / H3 level in each immune cell population, namely T cells (CD3 + CD19-), B-cell (CD3-CD19 +), mononuclear cells (CD14 + HLADR +) and granulocytes (CD14-HLADR-) through a formula. The whole blood sample can be preserved for 5 days under the condition of-60 to-90 DEG C after being subjected to one-step cracking and curing treatment. The method has good accuracy, reliability and stability.

This invention relates generally to agents and methods for treating the development or progression of a neurodegenerative disease. In particular, the present invention relates to CD14 antagonists for use in treating the development or progression of a neurodegenerative disease, including Motor Neurone Disease (MND) and Dementia disease or associated symptoms. The present invention further provides compositions including such agents.

The invention relates to the technical field of antibodies, in particular to an anti-mouse CD14 antibody and application thereof. The anti-mouse CD14 antibody comprises a heavy chain variable region and a light chain variable region, amino acid sequences of CDR1-3 of the heavy chain variable region are sequentially shown as SEQ ID NO.1-3, amino acid sequences of CDR1 and CD3 of the light chain variable region are shown as SEQ ID NO.4 and SEQ ID NO.5, and an amino acid sequence of CDR2 is RAS. The anti-mouse CD14 antibody provided by the invention can be specifically combined with mouse CD14, has relatively high affinity to the mouse CD14, and can be used for detecting the mouse CD14 or detecting or sorting CD14 + cells; when being used for cell sorting, the material has high enrichment degree on CD14 + cells, the purity of the sorted cells is high, and the material has a better application prospect in CD14 detection or CD14 + cell preparation.

The invention relates to a diagnostic microarray device comprising: a substrate, preferably formed of a glass material; wherein a plurality of probes attached or otherwise associated with the substrate, each probe being specific to one allele of a single nucleotide polymorphism (SNP), said SNR being selected from the group consisting of IL1B+3877, IL1B-511, and IL6-1363, and preferably IL10-592, CD14-260 and COX2+8473.

The invention provides a marker for prognosis of anti-MDA5 antibody positive dermatomyositis related interstitial pneumonia and application thereof, the marker is the proportion of CX3CR1 + CD14 + mononuclear cells in PBMC, and the marker is helpful for early recognition of high-risk patients, convenient for timely adjustment of therapeutic schedules and prevention of disease deterioration. The method for detecting the proportion of the CX3CR1 + CD14 + monocytes in the PBMC is mature and rapid, and can be used for multiple times of detection in different stages of diseases and dynamically monitoring the change of the illness state. The detection result of the proportion of the CX3CR1 + CD14 + monocytes in the PBMC is presented in a numerical form, the objectivity is high, the method is not influenced by the experience of an operator, and compared with subjective judgment of clinical symptoms and signs, the proportion of the CX3CR1 + CD14 + monocytes in the PBMC can be used as a prognostic marker to quantitatively evaluate the severity and treatment response of diseases, and an objective basis is provided for clinical decision making.

The invention relates to application of neutrophil subpopulation in pathogen infection detection. Specifically, the invention relates to an application of a protein, a polypeptide or a fragment thereof in detecting pathogen infection of a mammalian sample, and the protein, the polypeptide or the fragment thereof can be specifically combined with CD54, CD14 or a combination of CD54 and CD14; wherein the CD54 and the CD14 are proteins which are coupled with the neutrophil. The detection kit and the detection method provided by the invention are simple to operate, the detection sensitivity and specificity are far higher than those of CRP detection results, and early and rapid judgment can be made on infection-related diseases.

The present disclosure relates to CD14 + The present invention provides rAAV vectors and rAAV virions that specifically express exogenous nucleic acid sequences in cells. The rAAV vectors or virions are useful for specifically expressing exogenous nucleic acid sequences encoding, for example, cancer antigens, viral antigens, and / or bacterial antigens in monocytes and dendritic cells. rAAV-transduced CD14 + The cells can be used as antigen-presenting cells to induce antigen-specific T cell responses. The present disclosure further provides methods for producing rAAV virions and methods of immunotherapy.